JP2016505050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505050A5 JP2016505050A5 JP2015553921A JP2015553921A JP2016505050A5 JP 2016505050 A5 JP2016505050 A5 JP 2016505050A5 JP 2015553921 A JP2015553921 A JP 2015553921A JP 2015553921 A JP2015553921 A JP 2015553921A JP 2016505050 A5 JP2016505050 A5 JP 2016505050A5
- Authority
- JP
- Japan
- Prior art keywords
- chlorokynurenine
- pharmaceutical composition
- unit dose
- amount
- consisting essentially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HQLHZNDJQSRKDT-QMMMGPOBSA-N (2s)-2-amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=C(Cl)C=C1N HQLHZNDJQSRKDT-QMMMGPOBSA-N 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 239000004615 ingredient Substances 0.000 claims 5
- UAWVRVFHMOSAPU-UHFFFAOYSA-N 7-chlorokynurenic acid Chemical compound C1=CC(Cl)=CC2=NC(C(=O)O)=CC(O)=C21 UAWVRVFHMOSAPU-UHFFFAOYSA-N 0.000 claims 2
- 208000004454 Hyperalgesia Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 230000036642 wellbeing Effects 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000009251 neurologic dysfunction Effects 0.000 claims 1
- 208000015015 neurological dysfunction Diseases 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361849191P | 2013-01-22 | 2013-01-22 | |
| US61/849,191 | 2013-01-22 | ||
| PCT/US2014/012598 WO2014116739A1 (en) | 2013-01-22 | 2014-01-22 | Dosage forms and therapeutic uses l-4-chlorokynurenine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171786A Division JP6804497B2 (ja) | 2013-01-22 | 2018-09-13 | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505050A JP2016505050A (ja) | 2016-02-18 |
| JP2016505050A5 true JP2016505050A5 (OSRAM) | 2017-02-23 |
| JP6436913B2 JP6436913B2 (ja) | 2018-12-12 |
Family
ID=51228003
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015553921A Active JP6436913B2 (ja) | 2013-01-22 | 2014-01-22 | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 |
| JP2018171786A Active JP6804497B2 (ja) | 2013-01-22 | 2018-09-13 | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 |
| JP2020115273A Active JP7021298B2 (ja) | 2013-01-22 | 2020-07-03 | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 |
| JP2022015622A Pending JP2022070894A (ja) | 2013-01-22 | 2022-02-03 | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 |
| JP2024027330A Pending JP2024069257A (ja) | 2013-01-22 | 2024-02-27 | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018171786A Active JP6804497B2 (ja) | 2013-01-22 | 2018-09-13 | Ｌ−４−クロロキヌレニンの剤形及び治療的使用 |
| JP2020115273A Active JP7021298B2 (ja) | 2013-01-22 | 2020-07-03 | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 |
| JP2022015622A Pending JP2022070894A (ja) | 2013-01-22 | 2022-02-03 | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 |
| JP2024027330A Pending JP2024069257A (ja) | 2013-01-22 | 2024-02-27 | Ｌ－４－クロロキヌレニンの剤形及び治療的使用 |
Country Status (22)
| Country | Link |
|---|---|
| US (8) | US9993450B2 (OSRAM) |
| EP (4) | EP4385563A3 (OSRAM) |
| JP (5) | JP6436913B2 (OSRAM) |
| KR (5) | KR20230003410A (OSRAM) |
| CN (4) | CN113116877A (OSRAM) |
| AU (5) | AU2014209466B2 (OSRAM) |
| BR (1) | BR112015017535A2 (OSRAM) |
| CA (3) | CA2898619C (OSRAM) |
| CY (1) | CY1122403T1 (OSRAM) |
| DK (3) | DK3228313T3 (OSRAM) |
| ES (3) | ES2751138T3 (OSRAM) |
| HK (1) | HK1217170A1 (OSRAM) |
| HR (2) | HRP20240812T1 (OSRAM) |
| HU (1) | HUE067381T2 (OSRAM) |
| IL (3) | IL291831A (OSRAM) |
| MX (2) | MX375318B (OSRAM) |
| PL (2) | PL3228313T3 (OSRAM) |
| PT (3) | PT3228313T (OSRAM) |
| RS (1) | RS59687B1 (OSRAM) |
| SI (2) | SI3598971T1 (OSRAM) |
| WO (1) | WO2014116739A1 (OSRAM) |
| ZA (2) | ZA201505569B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230003410A (ko) | 2013-01-22 | 2023-01-05 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| SI3297619T1 (sl) * | 2015-05-22 | 2023-02-28 | Vistagen Therapeutics, Inc., | Terapevtske uporabe L-4-klorokinurenina |
| EP3347346A1 (en) * | 2015-09-08 | 2018-07-18 | Cephalon, Inc. | Prodrugs of chlorokynurenines |
| CA3127220C (en) | 2018-02-09 | 2024-11-19 | Vistagen Therapeutics Inc | SYNTHESIS OF 4-CHLOROKYNURENINS AND INTERMEDIARIES |
| CN109223785A (zh) * | 2018-10-29 | 2019-01-18 | 中国药科大学 | 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用 |
| WO2022082100A1 (en) * | 2020-10-16 | 2022-04-21 | Vistagen Therapeutics, Inc. | Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5086072A (en) | 1990-06-18 | 1992-02-04 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex |
| US5484814A (en) * | 1991-02-28 | 1996-01-16 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5360814A (en) | 1991-02-28 | 1994-11-01 | Merrell Dow Pharmaceuticals Inc. | NMDA antagonists |
| US5763393A (en) | 1996-05-17 | 1998-06-09 | Neurotherapeutics L.P. | Neuroactive peptides |
| TW518218B (en) | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| US7250394B2 (en) | 2001-08-20 | 2007-07-31 | Maiken Nedergaard | Treatment of glial tumors with glutamate antagonists |
| CA2497867A1 (en) | 2002-09-06 | 2004-03-18 | Durect Corporation | Delivery of modulators of glutamate-mediated neurotransmission to the inner ear |
| US20060063802A1 (en) | 2004-03-29 | 2006-03-23 | Matthieu Guitton | Methods for the treatment of tinnitus induced by cochlear excitotoxicity |
| AU2007235876A1 (en) | 2006-04-12 | 2007-10-18 | Probiodrug Ag | Enzyme inhibitors |
| EP1903028A1 (en) * | 2006-09-22 | 2008-03-26 | Werner Tschollar | Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| WO2009135091A1 (en) * | 2008-04-30 | 2009-11-05 | Medivation Technologies, Inc. | Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions |
| CN102159077A (zh) * | 2008-08-21 | 2011-08-17 | 吉瑞工厂 | 用于治疗神经性疼痛的方法 |
| US8680042B2 (en) | 2009-04-23 | 2014-03-25 | Universität Zürich Prorektorat Mnw | Methods of treating sickle cell anemia-related conditions with MK-801 or memantine |
| CA2763551A1 (en) * | 2009-06-17 | 2010-12-23 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
| CN102667485B (zh) | 2009-08-12 | 2015-04-22 | 福满代谢组技术有限公司 | 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质 |
| US8951968B2 (en) | 2009-10-05 | 2015-02-10 | Northwestern University | Methods of treating depression and other related diseases |
| EP2338873A1 (en) * | 2009-12-22 | 2011-06-29 | Gmeiner, Peter | New aminotetraline derivatives |
| US8846765B2 (en) * | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| KR20230003410A (ko) | 2013-01-22 | 2023-01-05 | 비스타젠 쎄라퓨틱스, 인크. | L-4-클로로키뉴레닌의 투여형 및 치료적 용도 |
| WO2014152835A1 (en) | 2013-03-14 | 2014-09-25 | Vistagen Therapeutics, Inc. | Synthesis of chiral kynurenine compounds and intermediates |
| MX378668B (es) | 2013-10-28 | 2025-03-10 | Naurex Inc | Profarmacos y moduladores de receptores nmda, sales y usos de estos. |
| SI3297619T1 (sl) | 2015-05-22 | 2023-02-28 | Vistagen Therapeutics, Inc., | Terapevtske uporabe L-4-klorokinurenina |
-
2014
- 2014-01-22 KR KR1020227044517A patent/KR20230003410A/ko not_active Ceased
- 2014-01-22 DK DK17170079T patent/DK3228313T3/da active
- 2014-01-22 AU AU2014209466A patent/AU2014209466B2/en active Active
- 2014-01-22 PL PL17170079T patent/PL3228313T3/pl unknown
- 2014-01-22 CA CA2898619A patent/CA2898619C/en active Active
- 2014-01-22 BR BR112015017535A patent/BR112015017535A2/pt not_active IP Right Cessation
- 2014-01-22 ES ES17170079T patent/ES2751138T3/es active Active
- 2014-01-22 CN CN202110384159.8A patent/CN113116877A/zh active Pending
- 2014-01-22 CN CN202110387953.8A patent/CN113209068A/zh active Pending
- 2014-01-22 PT PT171700792T patent/PT3228313T/pt unknown
- 2014-01-22 CA CA3216579A patent/CA3216579A1/en active Pending
- 2014-01-22 EP EP24164414.5A patent/EP4385563A3/en active Pending
- 2014-01-22 CN CN201480010060.XA patent/CN105073108A/zh active Pending
- 2014-01-22 CA CA3128321A patent/CA3128321C/en active Active
- 2014-01-22 WO PCT/US2014/012598 patent/WO2014116739A1/en not_active Ceased
- 2014-01-22 KR KR1020157022405A patent/KR102257284B1/ko active Active
- 2014-01-22 CN CN202110387961.2A patent/CN112933073A/zh active Pending
- 2014-01-22 KR KR1020217039478A patent/KR20210149905A/ko not_active Ceased
- 2014-01-22 EP EP17170079.2A patent/EP3228313B1/en active Active
- 2014-01-22 DK DK14743570.5T patent/DK2948140T3/en active
- 2014-01-22 ES ES19196366T patent/ES2980120T3/es active Active
- 2014-01-22 EP EP19196366.9A patent/EP3598971B1/en active Active
- 2014-01-22 US US14/762,015 patent/US9993450B2/en active Active
- 2014-01-22 ES ES14743570.5T patent/ES2635353T3/es active Active
- 2014-01-22 SI SI201432078T patent/SI3598971T1/sl unknown
- 2014-01-22 IL IL291831A patent/IL291831A/en unknown
- 2014-01-22 HU HUE19196366A patent/HUE067381T2/hu unknown
- 2014-01-22 PL PL19196366.9T patent/PL3598971T3/pl unknown
- 2014-01-22 KR KR1020217015432A patent/KR102335919B1/ko active Active
- 2014-01-22 HR HRP20240812TT patent/HRP20240812T1/hr unknown
- 2014-01-22 HK HK16105132.0A patent/HK1217170A1/zh unknown
- 2014-01-22 PT PT191963669T patent/PT3598971T/pt unknown
- 2014-01-22 JP JP2015553921A patent/JP6436913B2/ja active Active
- 2014-01-22 RS RS20191519A patent/RS59687B1/sr unknown
- 2014-01-22 SI SI201431410T patent/SI3228313T1/sl unknown
- 2014-01-22 EP EP14743570.5A patent/EP2948140B1/en active Active
- 2014-01-22 DK DK19196366.9T patent/DK3598971T3/da active
- 2014-01-22 MX MX2015009277A patent/MX375318B/es active IP Right Grant
- 2014-01-22 KR KR1020237021428A patent/KR20230098711A/ko not_active Ceased
- 2014-01-22 PT PT147435705T patent/PT2948140T/pt unknown
-
2015
- 2015-07-17 MX MX2020009966A patent/MX2020009966A/es unknown
- 2015-07-22 IL IL240090A patent/IL240090B/en active IP Right Grant
- 2015-08-03 ZA ZA2015/05569A patent/ZA201505569B/en unknown
-
2016
- 2016-02-08 US US15/018,219 patent/US9993453B2/en active Active
- 2016-11-02 ZA ZA2016/07581A patent/ZA201607581B/en unknown
-
2018
- 2018-05-14 US US15/978,855 patent/US10632091B2/en active Active
- 2018-06-08 US US16/003,816 patent/US10980758B2/en active Active
- 2018-06-08 US US16/003,793 patent/US10617663B2/en active Active
- 2018-06-08 US US16/003,804 patent/US20180369180A1/en not_active Abandoned
- 2018-09-13 JP JP2018171786A patent/JP6804497B2/ja active Active
- 2018-10-26 AU AU2018253600A patent/AU2018253600B2/en active Active
-
2019
- 2019-11-27 CY CY20191101244T patent/CY1122403T1/el unknown
- 2019-12-04 HR HRP20192189TT patent/HRP20192189T1/hr unknown
-
2020
- 2020-07-01 AU AU2020204420A patent/AU2020204420A1/en not_active Abandoned
- 2020-07-03 JP JP2020115273A patent/JP7021298B2/ja active Active
- 2020-07-16 IL IL276126A patent/IL276126B/en unknown
-
2022
- 2022-02-03 JP JP2022015622A patent/JP2022070894A/ja active Pending
- 2022-06-21 US US17/845,105 patent/US12036198B2/en active Active
- 2022-08-22 AU AU2022221382A patent/AU2022221382B2/en active Active
-
2024
- 2024-02-27 JP JP2024027330A patent/JP2024069257A/ja active Pending
- 2024-03-21 US US18/611,908 patent/US20250161251A1/en active Pending
- 2024-12-18 AU AU2024278564A patent/AU2024278564A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| JP2018507243A5 (OSRAM) | ||
| JP2014515373A5 (OSRAM) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2016505050A5 (OSRAM) | ||
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| JP2020516646A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| JP2017533972A5 (OSRAM) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2020500864A5 (OSRAM) | ||
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2019507786A5 (OSRAM) | ||
| JP2011500589A5 (OSRAM) | ||
| WO2012042197A3 (en) | Low dose pharmaceutical composition comprising zanamivir | |
| MX2024006270A (es) | Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| CN105209044B (zh) | 用于疼痛病症的治疗性米氮平组合物 | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2019535830A5 (OSRAM) | ||
| MX2022012693A (es) | Composicion que comprende metilfolato. | |
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи |